Actively Recruiting

Age: 40Years +
All Genders
Healthy Volunteers
ID07585370

Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine in Adults 40 Years or Older: A Multicenter Retrospective Cohort Study Based on Phase III Trial

Led by Jiangsu Province Centers for Disease Control and Prevention · Updated on 2026-05-13

24740

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

J

Jiangsu Province Centers for Disease Control and Prevention

Lead Sponsor

Z

Zhejiang Provincial Center for Disease Control and Prevention (Zhejiang Provincial Academy of Preventive Medicine)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the long-term effectiveness of a live attenuated herpes zoster vaccine in adults aged 40 years or older. This multicenter retrospective cohort study focuses on participants from a previous Phase III Clinical Trial conducted in 2020-2021, comparing those who originally received the vaccine with those who received a placebo. The study aims to assess the occurrence of herpes zoster over a period of up to six years after vaccination, including the impact of catch-up vaccination given after the vaccine’s marketing authorization in China.

CONDITIONS

Brief Title

Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine

Who Can Participate

Age: 40Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Individuals included in the E-mFAS from the Phase III Clinical Trial (NCT04334577) of the live attenuated herpes zoster vaccine conducted during 2020-2021
  • Individuals able to complete the study and provide verbal informed consent
  • Adults aged 40 years or older
Not Eligible

You will not qualify if you...

  • Individuals who developed herpes zoster during the original Phase III Clinical Trial follow-up period
  • Individuals known to have died before the retrospective study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Long-term Monitoring

Duration - From July 2021 to the survey date in 2026

Participants are observed for the incidence of herpes zoster following their original assignment to vaccine or placebo groups, including a catch-up vaccination period for some placebo participants.

Trial Site Locations

Total: 1 location

1

Jiangsu Provincial Center for Diseases Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)

Nanjing, Jiangsu, China

Actively Recruiting

Loading map...

Research Team

P

Pengfei Jin

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A Multicenter, Randomized, Double-blind, Placebo-controlled ...

Vaccine-Preventable Diseases

Actively Recruiting

1 location

A Randomized, Placebo Controlled, Observer-blind, Phase IV P...

Herpes Zoster

Actively Recruiting

8 locations

Reactogenicity, Safety and Immune Response Study of GSK's Pe...

Herpes Zoster

Actively Recruiting

31 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here